Impact of Three Genetic Musculoskeletal Diseases: a Comparative Synthesis of Achondroplasia, Duchenne Muscular Dystrophy and Osteogenesis Imperfecta

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2015 Feb 5

PMID 25649344

Citations 10

Authors

Maman Joyce Dogba

Frank Rauch

Erin Douglas

Christophe Bedos

Affiliations

Soon will be listed here.

Abstract

Achondroplasia, Duchenne muscular dystrophy, and osteogenesis imperfecta are among the most frequent rare genetic disorders affecting the musculoskeletal system in children. Rare genetic disorders are severely disabling and can have substantial impacts on families, children, and on healthcare systems. This literature review aims to classify, summarize and compare these non-medical impacts of achondroplasia, Duchenne muscular dystrophy and osteogenesis imperfecta.

Citing Articles

Osteogenesis Imperfecta: A Case Series and Literature Review.

Neri Morales C, Silva Amaro A, Cardona J, Bendeck J, Cifuentes Gaitan K, Valencia V Cureus. 2023; 15(1):e33864.

PMID: 36819366 PMC: 9935240. DOI: 10.7759/cureus.33864.

Role of Matrix Metalloproteinases in Musculoskeletal Diseases.

Kumar L, Bisen M, Khan A, Kumar P, Patel S Biomedicines. 2022; 10(10).

PMID: 36289739 PMC: 9598837. DOI: 10.3390/biomedicines10102477.

Functioning and well-being in older children and adolescents with achondroplasia: A qualitative study.

Pfeiffer K, Brod M, Smith A, Viuff D, Ota S, Charlton R Am J Med Genet A. 2021; 188(2):454-462.

PMID: 34643322 PMC: 9291880. DOI: 10.1002/ajmg.a.62534.

A qualitative study of the impacts of having an infant or young child with achondroplasia on parent well-being.

Pfeiffer K, Brod M, Smith A, Viuff D, Ota S, Charlton R Orphanet J Rare Dis. 2021; 16(1):351.

PMID: 34362417 PMC: 8344208. DOI: 10.1186/s13023-021-01978-z.

Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia.

Pfeiffer K, Brod M, Smith A, Gianettoni J, Viuff D, Ota S Am J Med Genet A. 2020; 185(1):33-45.

PMID: 33084192 PMC: 7756853. DOI: 10.1002/ajmg.a.61903.

References

Garralda M, McConachie H, Le Couteur A, Sriranjan S, Chakrabarti I, Cirak S . Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy. Child Care Health Dev. 2012; 39(3):449-55. DOI: 10.1111/j.1365-2214.2012.01387.x. View

Kohler M, Clarenbach C, Boni L, Brack T, Russi E, Bloch K . Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2005; 172(8):1032-6. DOI: 10.1164/rccm.200503-322OC. View

Engelbert R, Uiterwaal C, Gulmans V, Pruijs H, Helders P . Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000; 137(3):397-402. DOI: 10.1067/mpd.2000.107892. View

Fee R, Hinton V . Resilience in children diagnosed with a chronic neuromuscular disorder. J Dev Behav Pediatr. 2011; 32(9):644-50. PMC: 3217261. DOI: 10.1097/DBP.0b013e318235d614. View

Cole D . Psychosocial aspects of osteogenesis imperfecta: an update. Am J Med Genet. 1993; 45(2):207-11. DOI: 10.1002/ajmg.1320450211. View

Boekaerts M, Roder I . Stress, coping, and adjustment in children with a chronic disease: a review of the literature. Disabil Rehabil. 1999; 21(7):311-37. DOI: 10.1080/096382899297576. View

Paterson C, Ogston S, Henry R . Life expectancy in osteogenesis imperfecta. BMJ. 1996; 312(7027):351. PMC: 2350292. DOI: 10.1136/bmj.312.7027.351. View

Kemper A, Wake M . Duchenne muscular dystrophy: issues in expanding newborn screening. Curr Opin Pediatr. 2007; 19(6):700-4. DOI: 10.1097/MOP.0b013e3282f19f65. View

van Wijk E, Messelink B, Heijnen L, de Groot I . Prevalence and psychosocial impact of lower urinary tract symptoms in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2009; 19(11):754-8. DOI: 10.1016/j.nmd.2009.07.009. View

10.

Levac D, Colquhoun H, OBrien K . Scoping studies: advancing the methodology. Implement Sci. 2010; 5:69. PMC: 2954944. DOI: 10.1186/1748-5908-5-69. View

11.

Jutai J, Rigby P, Ryan S, Stickel S . Psychosocial impact of electronic aids to daily living. Assist Technol. 2001; 12(2):123-31. DOI: 10.1080/10400435.2000.10132018. View

12.

Manzur A, Kinali M, Muntoni F . Update on the management of Duchenne muscular dystrophy. Arch Dis Child. 2008; 93(11):986-90. DOI: 10.1136/adc.2007.118141. View

13.

Kinali M, Manzur A, Mercuri E, Gibson B, Hartley L, Simonds A . UK physicians' attitudes and practices in long-term non-invasive ventilation of Duchenne Muscular Dystrophy. Pediatr Rehabil. 2006; 9(4):351-64. DOI: 10.1080/13638490600622613. View

14.

Dogba M, Bedos C, Durigova M, Montpetit K, Wong T, Glorieux F . The impact of severe osteogenesis imperfecta on the lives of young patients and their parents - a qualitative analysis. BMC Pediatr. 2013; 13:153. PMC: 3852302. DOI: 10.1186/1471-2431-13-153. View

15.

Gollust S, Thompson R, Gooding H, Biesecker B . Living with achondroplasia: attitudes toward population screening and correlation with quality of life. Prenat Diagn. 2003; 23(12):1003-8. DOI: 10.1002/pd.743. View

16.

Kenneson A, Bobo J . The effect of caregiving on women in families with Duchenne/Becker muscular dystrophy. Health Soc Care Community. 2010; 18(5):520-8. DOI: 10.1111/j.1365-2524.2010.00930.x. View

17.

Arias R, Andrews J, Pandya S, Pettit K, Trout C, Apkon S . Palliative care services in families of males with Duchenne muscular dystrophy. Muscle Nerve. 2011; 44(1):93-101. DOI: 10.1002/mus.22005. View

18.

Balkefors V, Mattsson E, Pernow Y, Saaf M . Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. Physiother Res Int. 2013; 18(4):203-11. DOI: 10.1002/pri.1546. View

19.

Zurynski Y, Frith K, Leonard H, Elliott E . Rare childhood diseases: how should we respond?. Arch Dis Child. 2008; 93(12):1071-4. DOI: 10.1136/adc.2007.134940. View

20.

Ayme S, Kole A, Groft S . Empowerment of patients: lessons from the rare diseases community. Lancet. 2008; 371(9629):2048-51. DOI: 10.1016/S0140-6736(08)60875-2. View